JP2013518110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518110A5 JP2013518110A5 JP2012551232A JP2012551232A JP2013518110A5 JP 2013518110 A5 JP2013518110 A5 JP 2013518110A5 JP 2012551232 A JP2012551232 A JP 2012551232A JP 2012551232 A JP2012551232 A JP 2012551232A JP 2013518110 A5 JP2013518110 A5 JP 2013518110A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- mono
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 174
- 125000005843 halogen group Chemical group 0.000 claims 114
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 67
- -1 or R 13 and R 14 Chemical compound 0.000 claims 58
- 125000004093 cyano group Chemical group *C#N 0.000 claims 42
- 125000001424 substituent group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 208000002193 Pain Diseases 0.000 claims 20
- 239000003940 fatty acid amidase inhibitor Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 238000001356 surgical procedure Methods 0.000 claims 9
- 208000004296 neuralgia Diseases 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 208000005171 Dysmenorrhea Diseases 0.000 claims 6
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 6
- 208000004454 Hyperalgesia Diseases 0.000 claims 6
- 208000019695 Migraine disease Diseases 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 206010027599 migraine Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000030814 Eating disease Diseases 0.000 claims 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 235000014632 disordered eating Nutrition 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010047700 Vomiting Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003492 excitotoxic effect Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000003187 abdominal effect Effects 0.000 claims 3
- 206010053552 allodynia Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000004371 toothache Diseases 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710138657 Neurotoxin Proteins 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000318 excitotoxic Toxicity 0.000 claims 2
- 231100000063 excitotoxicity Toxicity 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000011514 reflex Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000009881 secretory diarrhea Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010021333 Ileus paralytic Diseases 0.000 claims 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 230000001769 paralizing effect Effects 0.000 claims 1
- 201000007620 paralytic ileus Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29908710P | 2010-01-28 | 2010-01-28 | |
| US61/299,087 | 2010-01-28 | ||
| PCT/US2011/022412 WO2011094209A1 (en) | 2010-01-28 | 2011-01-25 | Pharmaceutical compositions for the treatment of pain and other indicatons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013518110A JP2013518110A (ja) | 2013-05-20 |
| JP2013518110A5 true JP2013518110A5 (enExample) | 2014-03-13 |
Family
ID=44319717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551232A Withdrawn JP2013518110A (ja) | 2010-01-28 | 2011-01-25 | 疼痛および他の適応症の治療用の医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130030000A1 (enExample) |
| EP (1) | EP2528603A4 (enExample) |
| JP (1) | JP2013518110A (enExample) |
| KR (1) | KR20120123691A (enExample) |
| CN (1) | CN102858338A (enExample) |
| AU (1) | AU2011209754A1 (enExample) |
| BR (1) | BR112012018913A2 (enExample) |
| CA (1) | CA2786888A1 (enExample) |
| MX (1) | MX2012008801A (enExample) |
| RU (1) | RU2012136624A (enExample) |
| WO (1) | WO2011094209A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017079A1 (en) * | 2008-08-04 | 2010-02-11 | Merck & Co., Inc. | Oxazole derivatives useful as inhibitors of faah |
| CN102917704A (zh) * | 2010-04-08 | 2013-02-06 | 默沙东公司 | 可用作faah调节剂的噁唑衍生物 |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| ES2705244T3 (es) | 2010-06-16 | 2019-03-22 | Inflammatory Response Res Inc | Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| ES2660494T3 (es) | 2013-03-13 | 2018-03-22 | 14779507 | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática |
| CN105228700A (zh) | 2013-03-13 | 2016-01-06 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途 |
| EP2968309A4 (en) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| LT3077047T (lt) * | 2013-12-04 | 2019-08-26 | Galmed Research & Development Ltd. | Aramcholio druskos |
| WO2016036588A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| PT3595665T (pt) * | 2017-03-13 | 2024-11-21 | Lundbeck La Jolla Research Center Inc | Inibidores duplos de magl e faah |
| EP3649128A1 (en) | 2017-07-07 | 2020-05-13 | Syngenta Participations AG | Pesticidally active heterocyclic derivatives with sulfur containing substituents |
| KR102257685B1 (ko) | 2018-09-20 | 2021-05-31 | 성균관대학교산학협력단 | Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물 |
| CN110156710B (zh) * | 2019-04-30 | 2022-10-28 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种多取代噁唑类化合物的制备方法 |
| JP7464955B2 (ja) | 2020-02-27 | 2024-04-10 | 国立大学法人千葉大学 | ヨードオキサゾール化合物の製造方法、オキサゾール化合物の製造方法 |
| WO2021236518A1 (en) * | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| IL308880A (en) * | 2021-05-28 | 2024-01-01 | Ananda Scient Inc | Methods for the treatment of post-traumatic stress disorder and traumatic brain injury with cannabinoids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275493A1 (en) * | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| WO2006074025A1 (en) * | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| CA2602336A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| AU2008257154B2 (en) * | 2007-05-25 | 2014-03-06 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| US8455528B2 (en) * | 2008-06-11 | 2013-06-04 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as inhibitors of FAAH |
| WO2009151991A1 (en) * | 2008-06-11 | 2009-12-17 | Merck & Co., Inc. | Pyrazole derivatives useful as inhibitors of faah |
| WO2010017079A1 (en) * | 2008-08-04 | 2010-02-11 | Merck & Co., Inc. | Oxazole derivatives useful as inhibitors of faah |
-
2011
- 2011-01-25 AU AU2011209754A patent/AU2011209754A1/en not_active Abandoned
- 2011-01-25 KR KR1020127022379A patent/KR20120123691A/ko not_active Withdrawn
- 2011-01-25 RU RU2012136624/15A patent/RU2012136624A/ru not_active Application Discontinuation
- 2011-01-25 CA CA2786888A patent/CA2786888A1/en not_active Abandoned
- 2011-01-25 US US13/574,303 patent/US20130030000A1/en not_active Abandoned
- 2011-01-25 WO PCT/US2011/022412 patent/WO2011094209A1/en not_active Ceased
- 2011-01-25 BR BR112012018913A patent/BR112012018913A2/pt not_active IP Right Cessation
- 2011-01-25 EP EP11737514.7A patent/EP2528603A4/en not_active Withdrawn
- 2011-01-25 MX MX2012008801A patent/MX2012008801A/es not_active Application Discontinuation
- 2011-01-25 CN CN2011800171616A patent/CN102858338A/zh active Pending
- 2011-01-25 JP JP2012551232A patent/JP2013518110A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012136624A (ru) | Фармацевтические композиции для лечения боли и других показаний | |
| TWI739666B (zh) | 醫藥組成物 | |
| JP5941598B2 (ja) | ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 | |
| JP2012505891A5 (enExample) | ||
| CN110582489A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| CN113784970A (zh) | Erk抑制剂及其应用 | |
| JP2011510068A5 (enExample) | ||
| WO2018008711A1 (ja) | Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ | |
| JP2007514746A5 (enExample) | ||
| CN107074840B (zh) | 用于治疗炎性疾病和过度增殖性疾病的具有作为cPLA2抑制剂的活性的2-氧代噻唑化合物 | |
| CN103384661A (zh) | 盐皮质激素受体拮抗剂 | |
| JP2010516701A5 (enExample) | ||
| JP2007515489A5 (enExample) | ||
| JP2008540661A5 (enExample) | ||
| JP2014530243A5 (ja) | Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物 | |
| JP2010516700A5 (enExample) | ||
| JP2013521291A5 (enExample) | ||
| JP2007517006A5 (enExample) | ||
| CN114026068A (zh) | Ep2拮抗剂 | |
| RU2010116293A (ru) | Алкилтиопиримидины в качестве антагонистов crth2 | |
| TWI805727B (zh) | 經雜芳基取代之吡唑化合物及其醫藥用途 | |
| JP2024536862A (ja) | Ｉｌ－１７の調節因子としてのベンズイミダゾール | |
| CN104902893B (zh) | 盐皮质激素受体拮抗剂 | |
| JP2013525490A5 (enExample) | ||
| TW202233575A (zh) | 用於治療與lpa受體活性相關的病狀的化合物及組合物 |